Citi lifts Micron target to $1,300 on DRAM pricing strength

source:

[1] Micron Price Target Raised to $1,300 by Citi on Stronger DRAM Pricing, Undersupply (https://247wallst.com/investing/2026/09/23/mi ...)[2] MU Stock Gets Mixed Takes From Wall Street On Memory Tightness, DRAM Pricing Strength (https://finance.yahoo.com/markets/stocks/arti ...)[3] Micron Q4 Preview: Robust Memory Demand Supports A Bullish Outlook (https://seekingalpha.com/article/4948821-micr ...)[4] Micron Technology Stock Is Up Over 260%. Where It May Be Heading Next (https://www.forbes.com/sites/investor-hub/art ...)[5] Micron (MU) Gets $1,300 Price Target as Citi Sees More Memory Upside (https://coincentral.com/micron-mu-gets-1300-p ...)

Related News

Sep 23 2026, 17:35

Vertex's inaxaplin cuts proteinuria 42.7% as AMPLITUDE enrollment closes

Vertex Pharmaceuticals said its experimental kidney drug inaxaplin reduced protein leakage in two patient groups outside its main pivotal study, and that it has finished enrolling the trial that will decide whether the therapy reaches an accelerated approval filing. In the Phase 2b AMPLIFIED study, 22 patients with APOL1-mediated kidney disease (AMKD) and modest proteinuria saw urinary albumin to creatinine ratio (UACR) fall 42.7% from baseline at Week 13, Vertex said. UACR measures how much albumin — a blood protein — leaks into urine, and is the standard marker of kidney damage. A second cohort of 17 patients who also had type 2 diabetes recorded a 17.3% UACR reduction over the same period. "The modest proteinuria cohort, which included patients with and without FSGS, delivered remarkable reductions in proteinuria consistent with the original Phase 2a study in patients with AMKD and FSGS," Carmen Bozic, executive vice president of global medicines development and chief medical officer at Vertex, said. "We look forward to discussing the AMPLIFIED results with regulators in the context of the AMPLITUDE pivotal study." Total protein, measured by urine protein to creatinine ratio (UPCR), fell 44.7% in the modest proteinuria cohort and 25.4% in the diabetes cohort. The 42.7% UACR result matches the -43.4% UACR and -47.6% UPCR seen in Vertex's earlier Phase 2a trial in AMKD patients with focal segmental glomerulosclerosis, even though most participants in the new modest-proteinuria group did not carry an FSGS diagnosis. The diabetes cohort's confidence interval, -36.3% to 7.2%, crossed zero. Inaxaplin was generally safe and well tolerated. No serious adverse events were attributed to the drug, all adverse events were mild or moderate, and headache was the most common at 7.3%. Five patients had isolated, asymptomatic transaminase elevations that resolved — a liver signal worth monitoring given the drug is dosed daily and indefinitely. Vertex has completed full enrollment in AMPLITUDE, the Phase 2/3 trial testing inaxaplin in patients with severe proteinuria and no other kidney-damaging conditions. The pre-planned interim analysis is on track for early 2027, once the interim cohort reaches 48 weeks of treatment. A positive readout could support accelerated approval in the U.S. The final analysis will measure estimated glomerular filtration rate (eGFR) slope versus placebo after two years. AMKD affects roughly 150,000 people in the U.S. and Europe and has no approved therapy. Vertex's senior vice president of investor relations, Susie Lisa, said AMPLITUDE could unlock that full population, while an FDA label covering both AMPLIFIED cohorts would add about 100,000 patients. Guggenheim Securities analysts put the probability of success for inaxaplin in primary AMKD at 65%, and at 45% for the type 2 diabetes indication. The read-through lifted rival Maze Therapeutics, which is developing its own APOL1 inhibitor, MZE829. Truist Securities analyst Danielle Brill called the data a meaningful confirmation of APOL1 inhibition and said the market is large enough to support blockbuster sales for MZE829 even if it proves only comparable to inaxaplin. Truist rates Maze a Buy with a $64 price target. Vertex shares rose about 3% on the news, while Maze jumped roughly 25%. For Vertex holders, the AMPLIFIED results extend the case that inaxaplin works beyond the severe-proteinuria patients in AMPLITUDE, widening the commercial opportunity for what would be the first approved AMKD therapy. The next decisive event is the AMPLITUDE interim analysis in early 2027 — a binary readout that determines whether Vertex can file for accelerated approval or must wait on the two-year eGFR data. This article is for informational purposes only and does not constitute investment advice.

Sep 23 2026, 17:33

McDonald's hits 52-week low as $8.5B capex plan spooks analysts

McDonald's shares dropped to a fresh 52-week low on Wednesday after management told its 2026 Investor Day that US foot-traffic recovery will take longer than expected, while committing $8.5 billion to restaurant remodels, value-menu subsidies and digital infrastructure through 2030. The plan adds $1.5 billion to $2 billion in annual capital spending through the end of the decade, alongside rent relief for franchisees, a combination that analysts said constrains free cash flow and pushes share buybacks further out. UBS and RBC lowered their price targets on MCD the same morning, citing execution risk around the $1 cheeseburger value reset and weak sector-wide traffic. The stock traded below all of its major moving averages with a relative strength index in the mid-20s, a level that signals sustained selling pressure. McDonald's is now down roughly 30% from its year-to-date high set in late February. Heading into the session, Wall Street carried a consensus Moderate Buy rating with a mean price target near $313, a figure that now looks stale against the revised capex math. The company also pushed back its target of 50,000 global restaurants to 2028 from 2027, blaming development cost inflation and local permitting delays. The delay cuts near-term unit growth compounding and implies higher cumulative capital expenditure per location to reach the same long-term footprint. Second-quarter US same-store sales grew just 0.8%, and management's warning that persistent inflation and a strained low-income consumer are still suppressing visits landed harder than the capex headline. The $8.5 billion program is the financial core of the "McDonald's NEXT" strategy, which runs through 2030 and covers remodeling support, value-menu funding and beverage and digital buildout. Higher long-term bond yields are compounding the pressure. The 10-year Treasury yield touched a fresh 19-year high of 5.093% on Wednesday, lifting the discount rate applied to steady cash-flow consumer names and squeezing discretionary spending. That rate backdrop hits restaurant peers with similar defensive profiles, including Yum Brands and Restaurant Brands International, which trade on comparable cash-flow durability. September has historically been a weak month for McDonald's, a seasonal pattern that removes a near-term support for the shares. The read-through for holders is a de-rating that runs on estimate revisions rather than a single session. With the consensus target at $313 and the stock near its 52-week low, the gap between sell-side models and the tape is wide enough that further target cuts are likely as more firms fold the Investor Day numbers into their forecasts. The next hard checkpoint is the third-quarter earnings report, when management will have to show whether the added capital spending is translating into traffic or simply into a higher cost base. This article is for informational purposes only and does not constitute investment advice.

Sep 23 2026, 17:25

Fed October hike odds top 70% as inflation hits 4-year high

Traders now assign better than 70% odds to a quarter-point Federal Reserve increase at the Oct. 28 meeting, a repricing that followed hawkish remarks from Governor Michael Barr and an S&P Global report showing inflation at its highest in almost four years. The move extends a hawkish turn that began with the Fed's unanimous Sept. 16 vote to lift the federal funds target to 3.75% to 4%, its first increase since July 2023. Chair Kevin Warsh declined to offer forward guidance at that meeting's press conference, calling the move sober and responsible and arguing policy had never been tight to begin with. The data did the rest. The flash S&P Global US Composite PMI rose to 58.4 in September from 56.0 in August, with services at 58.7 against a 56.0 forecast and manufacturing at 57.0 versus 53.9 expected. Both gauges reached five-year highs. Average input costs across goods and services climbed at the fastest rate since October 2022, with firms citing fuel, transport and wage pressure. Backlogs of work grew at the quickest pace since May 2022 and factory hiring at the fastest since February 2021. Bond markets repriced the front end first. The 2-year Treasury yield rose almost 10 basis points to 4.874%, while the 10-year reached 5.058%, its highest print since July 2007. With the fed funds ceiling at 4.00%, the benchmark sits 106 basis points above the top of the policy range and the 2-year 87 basis points above it — the shape of a curve pricing more tightening, not less. Equities paid for it. The S&P 500 fell 0.54% to 7,722.88, the Nasdaq Composite dropped 1.06% to 26,954.38 and the Russell 2000 lost 1.03% to 2,860.11, with only 224 of the S&P's 503 members advancing. The VIX added 3.31% to 14.68, a level that points to orderly rotation out of long-duration winners rather than broad liquidation. Utilities, consumer discretionary and communication services each shed more than 1%, and PG&E fell 3.07% to $12.48, below its prior 52-week low. The transmission ran through every asset class. Gold futures dropped $58.30, or 1.33%, to $4,318.10 an ounce, bitcoin fell 2.30% to $84,255.74, and the dollar index held at 100.56 with the euro at $1.1446. The average 30-year fixed conforming mortgage rate rose to 7.12% from 6.97%, the highest since 2024, and both purchase and refinance applications declined. ## Why a 58.4 PMI Removes the Pause Trade The internals matter more than the headline. Historical comparisons put the September survey level consistent with annualized growth near 5% and the third quarter as a whole near 4%. A 4% quarter with input inflation at a 23-month high is not the combination a central bank that just hiked wants to see, and it takes a pause off the table for October. Demand is domestic. Goods exports kept declining and services export growth was modest, leaving the U.S. consumer and capital spending tied to the AI buildout as the engine. Neither is slowing on its own, which is why the selloff hit the longest-duration equities hardest — the Nasdaq fell twice as much as the S&P 500 and roughly six times as much as the Dow, which held at 51,772.80, down 0.18%. The last time the Fed raised rates into an inflation reading this hot was the 2023 tightening cycle, when the 2-year yield pushed above 5% and the S&P 500 lost 4.2% over the following month before recovering. Positioning today is less stretched, but the same mechanics apply: a higher risk-free rate compresses what investors will pay for cash flows a decade out. ## What the Next Six Weeks Decide The resolution date is Oct. 28, and the path runs through data. September payrolls and the next CPI print land before the meeting, and either can move the implied odds sharply in both directions. A softer inflation reading would unwind much of Wednesday's repricing quickly, given how fast the front end moved. The cross-asset chain also depends on crude. Brent closed below $100 for the first time since early September before reversing higher Wednesday, when an armed group shut a valve on the pipeline from Libya's El Sharara field, taking roughly a third of the country's output offline. November WTI traded at $91.92, up 1.55%. Higher crude keeps the inflation channel open and makes a 5% 10-year harder to break back below. For equities, the arithmetic is straightforward. At 7,722 the S&P 500 trades off a 5.058% risk-free benchmark, and every basis point higher compresses multiples on growth names. Until the 10-year closes back under 5%, rallies in high-multiple technology stocks are selling opportunities for fast money, and the market's direction runs through the bond market rather than through earnings. This article is for informational purposes only and does not constitute investment advice.